Hanmi Pharm Presents 11 Preclinical Research Results at AACR

"Deepening Innovative Research Based on Precision Medicine"

Hanmi Pharmaceutical will unveil 11 preclinical research results, the highest number in the domestic pharmaceutical and biotech industry, at the American Association for Cancer Research (AACR 2025).

Hanmi Pharmaceutical announced on the 14th that it will participate in AACR 2025, held from the 25th to 30th (local time) in Chicago, USA. At this event, the company plans to present a new biomarker for the next-generation targeted anticancer drug EZH1·2 dual inhibitor (HM97662) and provide research evidence that its anticancer efficacy can be maximized when combined with standard chemotherapy agents.

Additionally, research results on the anticancer efficacy of the orally administered 'selective HER2 inhibitor' (HM100714), being developed as a treatment for HER2 (human epidermal growth factor receptor 2) mutant cancers, against central nervous system tumors, as well as studies on overcoming resistance to 'Enhertu' (antibody-drug conjugate), will be disclosed.

For the 'MAT2A inhibitor' (HM100760), first revealed in October last year, the combined anticancer efficacy with PRMT5 inhibitors will be presented at this conference. The MAT2A inhibitor targets the metabolic vulnerabilities of cancer cells, showing promise in overcoming refractory cancers that are difficult to treat with existing therapies.

The mechanism of action and pharmacological activity of the new anticancer candidate 'SOS1 inhibitor' (HM101207) will also be announced for the first time. This new SOS1 inhibitor suppresses the binding between the SOS1 protein and KRAS, the most lethal protein causing cancer in the signaling cascade, regardless of mutation status, preventing KRAS activation.

Research outcomes of next-generation modality (therapeutic approach) based anticancer drugs using the 'mRNA platform,' which is gaining attention, will also be presented. At this conference, the 'STING mRNA anticancer drug,' which directly expresses the STING (Stimulator of IFN genes) protein to induce a strong anticancer immune response, will be unveiled for the first time. Activation of the STING protein promotes infiltration of various immune cells into tumors and enhances anticancer immune responses, contributing to the suppression of cancer progression.

Furthermore, research results on the 'next-generation p53-mRNA anticancer drug,' targeting p53 mutant cancers using mRNA platform technology, will be announced.

Preclinical research results of the next-generation immuno-oncology drug 'BH3120,' being primarily developed by the R&D center of Beijing Hanmi Pharmaceutical, Hanmi Group's local subsidiary in China, will also be introduced.

Choi In-young, head of the R&D center, stated, "Hanmi Pharmaceutical's research team is deepening innovative research based on precision medicine to present a new paradigm in cancer treatment. We are focusing on developing next-generation targeted therapies targeting specific cancer gene mutations such as EZH1·2, selective HER2, MAT2A, and SOS1, and we expect the realization of advanced precision treatments that selectively attack only cancer cells in the future."